California Attorney General Rob Bonta announced in a press conference that his office is filing a lawsuit against Eli Lilly (LLY), Novo Nordisk (NVO) and Sanofi (SNY) over insulin prices in the state. The suit also claims pharmacy benefit managers, or PBMs, CVS Caremark (CVS), Express Scripts (CI), and OptumRx (UNH) "have leveraged their market power to overcharge patients," according to Bonta. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
- Altimmune appoints Jordt as Chief Business Officer
- Eli Lilly price target raised to $400 from $395 at Barclays
- ProQR Therapeutics price target raised to $5 from $2 at Raymond James
- ProQR Therapeutics shares remain ‘fairly valued,’ says JMP Securities